5-FU biochemical modulation remains the most effective treatment in advanced colorectal cancer. In particular, association with folinic acid has reached tumor response rate ranging from 20 to 40%. However similar or higher results have been also observed by modifying pharmacological scheduling, in fact 5-FU protracted or 24 hours continuous infusion has obtained therapeutic efficacy even superior to 50%. On these bases we performed a phase II study with L-LV combined with 5-FU given by 24 hours infusion weekly. Patients with advanced, colorectal carcinoma were elegible; all pts required subcutaneous port insertion and portable external infusions pumps to allow outpatient treatment. Therapy was given as follows: L-LV 100 mg/sqm by 4 hrs infusion followed by 5-FU 2600 mg/sqm over 24 hrs continuous infusion combined with a fixed dose of oral L-LV (50 mg) every 4 hrs for 5 times. Thirty pts entered the study and 23 were evaluable for response: 23 male, 9 female; median age 57; median PS (ECOG) 1; 9 pts had received prior chemotherapy for advanced disease and 10 had received adjuvant chemotherapy. We observed: 1 complete response, 5 partial responses (26% OR), 1 minor response, 11 stable disease and 5 progressions. Most relevant toxicity observed till now is represented by: hand-foot syndrome grade I-II in 13 pt and grade III in 1 pt, reversible with treatment interruption; diarrhea grade III in 5 pts and grade II in 2 pts; fatigue grade III in 2 pts and grade II in 13 pts. Mielotoxicity, alopecia, nausea and vomiting were seen occasionaly. This treatment seems to show good activity regardless pts pre-treatment status, however, because of the recorded toxicity, it needs of further investigation and adequate clinical monitoring.
|Translated title of the contribution||Concurrent high dose 5-fluorouracil (5-FU) 24-hours infusion and oral L-leucovorin (L-LV) in advanced colorectal cancer: Preliminary data|
|Number of pages||4|
|Journal||Giornale Italiano di Oncologia|
|Publication status||Published - Jan 1 1994|
ASJC Scopus subject areas
- Cancer Research